Injective (INJ) is currently priced at $4.47, reflecting a slight decline of 1.63% over the past 24 hours. The daily trading range is narrow, with a high of $4.64 and a low of $4.47, indicating limited volatility during this period.

Volume stands at approximately 33.54 million, constituting 7.49% of the market cap, which suggests moderate trading activity relative to its overall market size. The moving averages present a bearish trend, with the shorter-term 8 SMA at $4.53 showing a decrease of 1.34%, while the 55 SMA at $4.65 and the 144 SMA at $4.66 indicate stronger downward momentum with declines of 3.85% and 4.09%, respectively.

The 1-hour RSI is notably low at 16, indicating that INJ is currently oversold in the short term. The 7-day RSI at 48 suggests a neutral stance, but both the 7-day and 14-day price changes reveal a bearish trend, with declines of approximately 2.44% and 9.48% respectively.

Furthermore, the 30-day price change shows a significant downturn of nearly 22%, which could signal longer-term bearish sentiment among traders. Given these technical indicators and the lack of bullish momentum, it is unlikely that the price will rebound significantly in the near term.

In conclusion, the current technical and fundamental data points to a cautious outlook for Injective (INJ). Therefore, I recommend a Sell rating as the bearish trends across multiple timeframes suggest further downside potential in the short to medium term.